Thomas Christely takes ceo role at Silence Therapeutics
Based at RNAi firm’s facility in Berlin, Germany
Christely brings more than 20 years’ experience in corporate and business development and finance to the firm. He was instrumental in the merger of Silence Therapeutics (formerly Atugen) with Silence Therapeutics (formerly SR Pharma) and admission to the Alternative Investment Market of the London Stock Exchange.
Christely joined Atugen in 2001 as chief financial officer and became chief operating officer in 2002 before being appointed its chief executive in 2006.
Prior to joining Silence, he was senior vp and cfo at OXO Chemie, a Swiss pharmaceutical company, and founded its subsidiary OXO Chemie Inc in San Francisco, where he stayed from 1997 until 2000.
